

AGENDA & MEETING NOTICE

Washington State Pharmacy and Therapeutics Committee

Date: June 16, 2010

Time: 9:00 a.m. – 4:00 p.m.

Location: Marriott Hotel

3201 South 176th Street

Seattle, WA 98188

9:00 a.m. – 9:05 a.m.	Welcome & Introductions	T. Vyn Reese, M.D. P&T Committee Chair
9:05 a.m. – 9:20 a.m.	Drug Class Review – Scan Calcium Channel Blockers <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	Kim Peterson OHSU <i>Stakeholders</i> P & T Committee
9:20 a.m. – 9:40 a.m.	Drug Class Review – Scan Drugs to treat Overactive Bladder <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	Kim Peterson OHSU <i>Stakeholders</i> P & T Committee
9:40 a.m. – 10:00 a.m.	Drug Class Review – Scan Antiemetics <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	Kim Peterson OHSU <i>Stakeholders</i> P & T Committee
10:00 a.m. – 10:20 a.m.	Drug Class Review – Scan Macrolides <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	Sujata Thakurta OHSU <i>Stakeholders</i> P & T Committee
10:20 a.m. – 10:45 a.m.	Break	All
10:45 a.m. – 11:05 a.m.	Drug Class Review – Scan Estrogens – Hormone Therapy <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	Susan Carson OHSU <i>Stakeholders</i> P & T Committee
11:05 a.m. – 11:30 a.m.	Drug Class Review – Scan Proton Pump Inhibitors <i>Stakeholder comments: Limit 3 minutes per person.</i> P & T Committee discussion and motions	Susan Carson OHSU <i>Stakeholders</i> P & T Committee
12:00 p.m. – 1:00 p.m.	Lunch – <i>On your own</i>	All
1:00 p.m. – 4:00 p.m.	Drug Utilization Review (DUR) for Washington <u>1) Background:</u> Abuse of stimulant drugs used in the treatment of ADHD is a growing problem within Washington State. <u>2) Today's Presentation:</u> The Health and Recovery Services Administration and the Division of Behavioral Health and Recovery will present data, tools, and references related to stimulant abuse. Processes will be suggested to identify and address stimulant abuse in the office based setting. <u>3) Expected Outcome:</u> The DUR Board will be asked to comment and give guidance on measures to track abuse and possible unintended consequences of administrative programs. <i>Stakeholder comments: Limit 3 minutes per person.</i>	Jeff Thompson, MD Chief Medical Officer HRSA David Albert DSHS/HRSA/DBHR Victoria Roberts DSHS/HRSA/DBHR
4:00 p.m.	Adjourn	

Special notes:

If you are a person with a disability and need a reasonable accommodation or have questions, please call Regina Chacón at (206) 521-2027.